Profile data is unavailable for this security.
About the company
LianBio is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-87.98m
- Incorporated2019
- Employees163.00
- LocationLianBio103 Carnegie Center DriveSuite 309, Suite 215PRINCETON 08540United StatesUSA
- Phone+1 (609) 486-2308
- Websitehttps://www.lianbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Raphael Pharmaceutical Inc | 0.00 | -1.57m | 30.79m | 0.00 | -- | -- | -- | -- | -0.0929 | -0.0929 | 0.00 | -0.0055 | 0.00 | -- | -- | -- | -624.25 | -- | -- | -- | -- | -- | -- | -- | -- | -173.44 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -40.09m | 31.31m | 15.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0482 | 0.00 | -- | -- | 0.00 | -303.75 | -- | -1,499.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Alterola Biotech Inc | 0.00 | -2.88m | 32.28m | 1.00 | -- | -- | -- | -- | -0.0027 | -0.0027 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -47.24 | -- | -63.88 | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -- | -- | 73.07 | -- | -- | -- |
| ImmuCell Corp | 21.28m | -3.90m | 32.42m | 74.00 | -- | 1.31 | -- | 1.52 | -0.5030 | -0.5030 | 2.75 | 3.18 | 0.494 | 2.29 | 9.03 | 269,401.50 | -9.05 | -5.16 | -9.97 | -5.53 | 27.55 | 40.04 | -18.31 | -12.64 | 1.00 | -8.14 | 0.3204 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| Quince Therapeutics Inc | 0.00 | -30.28m | 32.85m | 32.00 | -- | 0.4429 | -- | -- | -0.7599 | -0.7599 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -23.97 | -42.72 | -25.27 | -46.06 | -- | -- | -- | -- | -- | -- | 0.1542 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| LianBio - ADR | 0.00 | -87.98m | 33.60m | 163.00 | -- | 0.1647 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| Unicycive Therapeutics Inc | 0.00 | -37.82m | 34.10m | 14.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | 0.5779 | 0.00 | -- | -- | 0.00 | -92.81 | -218.20 | -221.58 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Lipocine Inc | 4.71m | -8.97m | 34.28m | 17.00 | -- | 1.42 | -- | 7.28 | -1.71 | -1.71 | 0.8889 | 4.51 | 0.1585 | -- | 67.70 | 277,138.80 | -30.16 | -39.32 | -32.00 | -45.87 | -- | -- | -190.35 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| Immuneering Corp | 0.00 | -54.18m | 35.29m | 65.00 | -- | 0.4483 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -16.58m | 35.35m | 8.00 | -- | 2.09 | -- | -- | -3.26 | -3.26 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -68.36 | -95.57 | -108.01 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Mink Therapeutics Inc | 0.00 | -20.59m | 35.65m | 31.00 | -- | -- | -- | -- | -0.5964 | -0.5964 | 0.00 | -0.585 | 0.00 | -- | -- | 0.00 | -175.32 | -- | -3,661.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| IGC Pharma Inc | 1.35m | -13.00m | 35.88m | 67.00 | -- | 4.32 | -- | 26.68 | -0.2168 | -0.2168 | 0.0229 | 0.1098 | 0.0993 | 0.292 | 18.42 | 20,074.63 | -96.01 | -42.46 | -113.83 | -46.07 | 54.50 | 20.95 | -966.54 | -730.00 | 0.9252 | -- | 0.0188 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
| Cue Biopharma Inc | 7.02m | -49.97m | 36.12m | 53.00 | -- | 1.20 | -- | 5.14 | -1.07 | -1.07 | 0.1495 | 0.6175 | 0.1035 | -- | 8.80 | 132,452.80 | -73.69 | -57.45 | -96.35 | -68.41 | -- | -- | -711.84 | -810.87 | -- | -- | 0.1935 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.05m | 36.28m | 4.00 | -- | 6.02 | -- | -- | -1.17 | -1.17 | 0.00 | 0.3807 | 0.00 | -- | -- | 0.00 | -194.65 | -- | -283.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 29 Feb 2024 | 57.56m | 53.26% |
| RhumbLine Advisers LPas of 31 Mar 2024 | 125.46k | 0.12% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 14.62k | 0.01% |
| FNY Capital Management LPas of 31 Mar 2024 | 13.80k | 0.01% |
| UBS Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Mar 2024 | 0.00 | 0.00% |
| Anson Funds Management LPas of 31 Mar 2024 | 0.00 | 0.00% |
| Casdin Capital LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Myda Advisors LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| HighMark Wealth Management LLCas of 31 Mar 2024 | 0.00 | 0.00% |
